C12N 2770/36152
Relating to complementing cells and packaging systems for producing virus or viral
Official title: relating to complementing cells and packaging systems for producing virus or viral particles
C12N2770/36152 (Relating to complementing cells and packaging systems for producing virus or viral) appears on 29 US grants and 36 published applications in this corpus.
Search patents in C12N- Granted patents
- 29
- Published applications
- 36
- Assignees
- 26
- Inventors
- 58
- Latest grant
- 18 Feb 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 2 | 0 |
| 2001 | 2 | 1 |
| 2002 | 2 | 1 |
| 2003 | 3 | 3 |
| 2004 | 0 | 5 |
| 2005 | 0 | 1 |
| 2006 | 3 | 2 |
| 2007 | 1 | 0 |
| 2008 | 2 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 4 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 1 | 1 |
| 2015 | 1 | 2 |
| 2016 | 3 | 3 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 2 |
| 2020 | 4 | 1 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 1 | 2 |
| 2024 | 1 | 1 |
| 2025 | 1 | 2 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Alphavirus replicon particle18 Feb 2025US 12,227,770 B2VLP Therapeutics, LLC
- Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon30 Jul 2024US 12,049,639 B2The USA, as represented by the Secretary, Dept. of Health and Human Services
- Cancer immunotherapy by delivering class II MHC antigens using a VLP-replicon8 Aug 2023US 11,718,861 B2The USA, as represented by the Secretary, Dept. of Health and Human Services
- T7 alpha viral vector system13 Oct 2020US 10,801,041 B2Orbis Health Solutions LLC
- Retrovirus packaging cell7 Jul 2020US 10,704,032 B2UCL Business PLC
- Virus-like vesicles (vlvs) based vaccines and methods of preventing, ameliorating, and/or treating covid-19 and/or hepatocellular carcinoma (hcc)5 Feb 2026US 2026/0034208 A1Yale University
- Alphavirus replicon particle24 Apr 2025US 2025/0129342 A1VLP Therapeutics, LLC
- Engineered viral nucleic acids for directed evolution and uses thereof13 Feb 2025US 2025/0051796 A1Alphinia PTY LTD
- Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof28 Nov 2024US 2024/0392255 A1Academisch Ziekenhuis Groningen
- Feline Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine9 Nov 2023US 2023/0355741 A1Intervet Inc.
Most cited
By later US patents
- Alphavirus RNA replicon systems100US 5,792,462 AThe United States of America as represented by the Secretary of the Army · 1998
- Alphavirus RNA replicon systems77US 6,156,558 AThe University of North Carolina at Chapel Hill · 2000
- Alphavirus replicon vector systems45US 7,045,335 B2AlphaVax, Inc. · 2006
- Compositions and methods for packaging of alphavirus vectors41US 6,329,201 B1Chiron Corporation · 2001
- Alphavirus replicon vector systems39US 7,425,337 B2AlphaVax, Inc. · 2008